 |
|
Cutaneous Adverse Reactions Associated With Calcium Channel Blockers
Robert Stern, MD;
J. H. Khalsa, PhD
Arch Intern Med. 1989;149(4):829-832.
Abstract
| |
• The calcium channel blockers, nifedipine, verapamil, and diltiazem, are widely used for the treatment of cardiovascular disease. In spite of their widespread use, little data about the frequency and spectrum of cutaneous reactions associated with these agents have been published. Based on reports provided to the FDA's Division of Epidemiology and Drug Surveillance, and the American Academy of Dermatology's Adverse Drug Reaction Reporting System, it appears that the frequency of adverse cutaneous events associated with these drugs is low, but that occasionally severe reactions are associated with the use of these drugs. Among the more serious reactions associated with the calcium channel blockers are toxic epidermal necrolysis with diltiazem, Stevens-Johnson syndrome and erythema multiforme, which have been associated with all three drugs in this class, and exfoliative dermatitis, which has also been reported with all three agents. Most serious reactions associated with these agents occur within two weeks of initiating drug therapy. These findings suggest that calcium channel blockers are occasional causes of a wide spectrum of cutaneous reactions and should be considered as possible causative factors in patients who develop adverse cutaneous reactions while using these drugs.
(Arch Intern Med. 1989;149:829-832)
Author Affiliations
From the Department of Dermatology, Beth Israel Hospital, Harvard Medical School, Boston (Dr Stern) and the Research Office of Epidemiology and Biostatistics, Food and Drug Administration, Rockville, Md (Dr Khalsa).
Footnotes
Accepted for publication November 8,1988.
The opinions expressed are those of the authors and do not represent the opinions of the United States Food and Drug Administration.
Reprint requests to Beth Israel Hospital, 330 Brookline Ave, Boston, MA 02215 (Dr Stern)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Diltiazem induces severe photodistributed hyperpigmentation: case series, histoimmunopathology, management, and review of the literature.
Saladi et al.
Arch Dermatol 2006;142:206-210.
ABSTRACT
| FULL TEXT
ORAL ADVERSE DRUG REACTIONS TO CARDIOVASCULAR DRUGS
Torpet et al.
CROBM 2004;15:28-46.
ABSTRACT
| FULL TEXT
Drug-Induced Hypersensitivity Syndrome in Pediatric Patients
Carroll et al.
Pediatrics 2001;108:485-492.
ABSTRACT
| FULL TEXT
Diltiazem-Associated Photodistributed Hyperpigmentation: A Review of 4 Cases
Scherschun et al.
Arch Dermatol 2001;137:179-182.
ABSTRACT
| FULL TEXT
Drug-Induced Pseudolymphoma and Hypersensitivity Syndrome: Two Different Clinical Entities
Callot et al.
Arch Dermatol 1996;132:1315-1321.
ABSTRACT
Diltiazem and Subacute Cutaneous Lupus Erythematosus-Like Lesions
Crowson and Magro
NEJM 1995;333:1429-1429.
FULL TEXT
Drug-Induced Fever due to Diltiazem
Dominguez and Hamill
Arch Intern Med 1991;151:1869-1870.
ABSTRACT
|
